Clinical trial

Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®

NCT01075880

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-05-01

PhaseN/A

Study timeline

Study start (unknown)2009-05-01Date precision: month

Registry last updated2013-09-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosis, Relapsing-Remittingunresolved

Interventions

Rebif (Interferon beta-1a)DRUG

Sponsors & collaborators

Merck KGaA, Darmstadt, Germanylead sponsor

Merck spol.s.r.o., Czech Republiccollaborator

Mapped research locations

PragueCzechia2 BrnoCzechia2 OlomoucCzechia1 Hradec KrálovéCzechia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01075880 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.